

Most common cause of anemia worldwide

- Iron is essential for the production of hemoglobin, and a deficiency leads to impaired erythropoiesis and iron deficiency anemia (IDA).
- critical role in oxygen delivery
- DNA synthesis
- cellular transport
- ■Hepcidin, the key peptide involved in iron regulation, is produced in the liver and is a negative regulator of iron absorption.
 - ✓ production increases with inflammation

in the frail

decreases in response to hypoxia, anemia, and iron deficiency.

TREATMENT

Severe and highly symptomatic: RBC transfusion

Severely reduced hematocrit or myocardial ischemia


Oral iron

GI side effects very common (Constipation, diarrhea, epigastric pain, nausea/vomiting, Black, green or tarry stools)

to be given once daily or avery other day

Intravenous iron

- √ oral iron may not be adequate treatment
- Used when GI side effects prohibit oral replacement
- √ Or patients with malabsorption (celiac disease, inflammatory bowel disease)
- undergone resection of the stomach or small bowel
- Pregnancy (more rapid repletion of iron)



OUTLINES

- Definition
- Etiology and Types of RF
- Hypoxemic RF (ARDS)
- **♦ Vetilatory Failure (Hypercapnic)**
- Other types of Respiratory Failure
- Diagnosis
- Management

- aa graehent
- nivasine ve noninvasine ventilation
- Hypoxia mechanism
- Hyper et Rf


Types of respiratory failure			
	Type 1 (hypoxemic respiratory failure)	Type 2 (hypercapnic respiratory failure)	
Definition	Respiratory failure characterized by hypoxemia and normocapnia or hypocapnia on arterial blood gas analysis	Respiratory failure characterized hypercapnia and normoxemia or hypoxemia on arterial blood gas analysis	
PaO	↓ (< 60 mmHg)	Normal or ↓ (< 80 mm Hg)	
PaCO	Normal or ↓ (< 33 mm Hg)	↑ (> 50 mmHg)	
		The transfer of the state of th	




HYPOXEMICVS HYPERCAPNIC (VENTELATORY) RESPIRATORY FAILURE

Hypoxemic Respiratory Failure	Hypercapnic Respiratory Failure
Known as: Type I ARF, Lung Failure, Oxygenation Failure, Respiratory Insufficiency	Known as: Type II ARF, Pump Failure, Ventilatory Failure
Definition: The failure of lungs and heart to provide adequate O ₂ to meet metabolic needs	Definition: The failure of the lungs to eliminate adequate CO ₂
Criteria: $PaO_2 < 60 \text{ mmHg on } F_1O_2 \ge .50$ or $PaO_2 < 40 \text{ mmHg on any } F_1O_2$ $SaO_2 < 90$	Criteria: Acute ↑ in PaCO₂ > 50 mmHg or Acutely above normal baseline in COPD with concurrent ↓ in pH < 7.30
Basic Causes: R-L shunt V/Q mismatch ^{PL} Alveolar hypoventilation Diffusion defect Inadequate FIO ₂	Basic Causes: Pump failure (drive, muscles, WOB) ↑ CO₂ production R-L shunt ↑ Deadspace

TYPES OF HYPOXEMIA






	Causes of hypoxemia ((1.4 x Pacoz) - Pabz)X		
	Example	A-a gradient	Corrects with supplemental O ₂ ?
Reduced PiO ₂	High altitude	Normal	Yes
Hypoventilation	CNS depression, neuromuscular weakness	Normal	Yes
V/Q mismatch	Pulmonary embolism, COPD	Increased	Yes
Diffusion limitation	Emphysema, ILD	Increased	Yes
Intrapulmonary shunt (V/Q = 0)	Pneumonia, pulmonary edema, atelectasis	Increased	No
Intracardiac shunt (right to left)	Tetralogy of Fallot, Eisenmenger syndrome	Increased	No re of inspired oxygen, VIQ = ventilation/perfusion

A-a gradient = alveolar-to-arterial oxygen gradient; ILD = interstitial lung disease; PiO₂ = partial pressure of inspired oxygen; ViQ = ventilation/perfusion ratio.







Box 16.5 Some indications for the use of non-invasive ventilation (NIV)

- Acute exacerbation of COPD (pH <7.35)</p>
- Cardiogenic pulmonary oedema
- Chest wall deformity/neuromuscular disease (hypercapnic respiratory failure)
- Obstructive sleep apnoea
- Severe pneumonia (see Box 15.7)
- Asthma (occasionally)
- Weaning patients from invasive ventilation


Contraindications include facial or upper airway surgery, reduced conscious level, inability to protect the airway.

Modified from BTS guidelines after 1997, http://www.british thoracic society.co.uk.

TYPES OF HYPOXEMIA

Colonlated by the ABGs

if it was 7 expected



Causes of hypoxemia				
	Example	A-a gradient Normal	Corrects with supplemental O ₂ ? Yes	
Reduced PiO ₂	High altitude			
Hypoventilation	CNS depression, neuromuscular weakness	Normal	Yes	
V/Q mismatch	Pulmonary embolism, COPD	Increased	Yes	
Diffusion limitation	Emphysema, ILD	Increased	Yes	
intrapulmonary shunt (V/Q = 0)	Pneumonia, pulmonary edema, atelectasis	Increased	No	
Intracardiac shunt (right to left)	Tetralogy of Fallot, Eisenmenger syndrome	Increased	No	

A-a gradient = alveolar-to-arterial oxygen gradient; ILD = interstitial lung disease; PiO₂ = partial pressure of inspired oxygen; V/Q = ventilation/perfusion ratio.

His is high are


Seizure	Syncope
Aura, focal symptoms, olfactory hallucinations, automatism (ex. lip smacking) before	Prodromal presyncope, palpitations, diaphoresis before
Myoclonic jerks before LOC	Myoclonic jerks after LOC
Usually between 1-2 minutes	Brief, generally <1 minute
EMS vitals: usually BP & HR generally elevated (exception: rare types of temporal lobe seizure can cause bradycardia)	EMS vitals: could have low BP & HR
Post-ictal confusion	Rapid recovery
More often horizontal deviation or flickering of eyelids, blank stare	Vertical deviation (rolling back), can also see flickering of eyelids
Eyes open	Usually eyes closed or rolled back
Lateral tongue biting	

TABLE 38-2

Glasgow Coma Scale

BEHAVIOR	RESPONSE	SCORE
Eye opening	Spontaneously	4
response	To speech	3
	To pain	2
	No response	1
Best verbal	Oriented to time, place, and person	5
response	Confused	4
***	Inappropriate words	3
	Incomprehensible sounds	2
	No response	1
Best motor	Obeys commands	6
response	Moves to localized pain	5
	Flexion withdrawal from pain	4
	Abnormal flexion (decorticate)	3
	Abnormal extension (decerebrate)	2
	No response	1
Total score:	Best response	15
	Comatose client	8 or less
	Totally unresponsive	3


DIAGNOSIS



Blood smear: thalassemia.

Target cells (arrows)


circulating nucleated red blood cells (arrowhead).



normed



CHYPOCHROMIC (PALE)



* Treatment


- 1. Symptomatic
 - a. Allopurinol (Decreases Uric Acid)
 - b. Antihistamines
 - 2. Chronic phase
 - a. Tyrosine Kinase Inhibitors (Imatinib, Dasatinib, or nilotinib)
 - b. Interferon-α: may improve response to tyrosine kinase inhibitors
 - c. Hydroxyurea in palliative setting
 - d. Bone marrow transplantation (Curative)


- 3. Accelerated phase or blast phase
 - a. Tyrosine Kinase Inhibitors
 - b. AML Chemotherapy
 - c. Stem cell transplantation (May be curative)




- -Patients with significant erythromelagia but low risk of thrombosis (< 1,500,000 @ give low-dose aspirin
- -Patients at high risk of thrombosis (> 60 Y.O, history of thrombosis, Cardiovascular risk or platelets >1,500,000) ② give cytoreductive therapy hydroxyurea (Goal is to reduce platelets to < 400,000). Anagrelide, busulfan and interferon alpha are 2nd line therapies
- -Splenectomy not recommended (increased risk of bleeding episodes, thrombosis)

Prognosis





- -Advance age
- -Cytopenias
- -presence of circulating blast cells,
- -constitutional symptoms



t++71 031491.

lenkomoid reaction major + minor citeria

Death occur mostly from infections, hemorrhage, cardiac failure postsplenectomy mortality and transformation into acute leukemia

- Dynamic International Prognostic Scoring System plus (DIPSS-plus) for IMF uses 8 factors to determine mean survival :
- Age older than 65 years
- · Hemoglobin level less than 10 g/dl
- Leukocyte count higher than 25 *109 /L
- PLATLET COUNT LOWER THAN 100* 109 /L
- · Circulating blasts of 1% or more
- Constitutional symptoms
- Red blood cell transfusion dependency
- Unfavorable karyotype

Classifications:

Low risk (0 adverse points) = 15.4

Intermediate 1 risk (1 adverse point) = 6.5

Intermediate 2 risk (2-3 adverse points)=2.9

High risk (4-6 adverse points)=1.3